Our Mission
Our mission is to develop therapeutics to treat rare, chronic, and serious infectious diseases in areas of high unmet medical need. As leaders in the field of antimicrobials, we also have both an obligation and a strong desire to combine our drug discovery and development expertise with resources available from public and private organizations to address high unmet needs in global health.
Management
Eric Easom
Co-Founder, President & CEO
Director
Mr. Easom has over 29 years of leadership experience in the biotechnology and pharmaceutical industry and has spent the last 15 years focused on bringing innovation to address significant unmet needs in infectious diseases, focused on the developing world. In addition to being the Founder, President and CEO of AN2 Therapeutics, Mr. Easom also serves on the Board of Directors of AN2 Therapeutics. Mr. Easom serves on the Board of Directors for the Chagas Disease Foundation, Resilient Biotics, and is an advisor for the California Life Sciences Institute. Previously, Mr. Easom spent 9 years at Anacor Pharmaceuticals, which was acquired by Pfizer. During his tenure, he led Anacor’s R&D on neglected disease programs that achieved global prominence, working in close partnership with the Bill and Melinda Gates Foundation, the Wellcome Trust, The University of Georgia (Tarleton Lab), Medicines for Malaria Venture, Global Alliance for Veterinary Medicine, Drugs for Neglected Disease initiative (DNDi), GlaxoSmithKline (GSK), Eli Lilly & Company, the University of California, San Francisco, Colorado State, DTRA, Walter Reed, the London School of Hygiene and Tropical Medicine, TB Alliance, the global Anti-Wolbachia Consortium, and numerous other partners. The Anacor Neglected Diseases team raised over $80M in funding and discovered over a dozen potentially transformational medicines for diseases such as malaria, tuberculosis, river blindness, cryptosporidiosis and trypanosome diseases including Chagas disease, African sleeping sickness, and leishmaniasis. Mr. Easom also served on the Board of Directors for the Infectious Disease Research Institute, from 2007-2014, serving as Chairman from 2009-2013. The majority of his early career was at Eli Lilly and Company, followed by McKesson and other biotechnology companies such as MedImmune and InteKrin Therapeutics. Mr. Easom earned an MBA from Indiana University, Kelley School of Business and a BS and Masters in Electrical Engineering from the University of Louisville.
Sanjay Chanda, Ph.D.
Chief Development Officer
Dr. Sanjay Chanda brings over twenty-five years of experience in drug development, including product development, regulatory affairs, and product registration to AN2 Therapeutics, where he is the Chief Development Officer. Previously, Dr. Chanda served as Chief Development Officer at Tioma Therapeutics, and co-founded Auration, Inc., an early-stage pharmaceutical company focused on treating chronic hearing loss in humans. Prior to his CDO role at Tioma Therapeutics, Dr. Chanda was the Senior Vice President of Drug Development at Anacor Pharmaceuticals (acquired by Pfizer). At Anacor, he was responsible for all aspects of CMC and Preclinical Safety and played key leadership roles in the development and approvals of KERYDIN® for the treatment of onychomycosis and EUCRISA® for the treatment of atopic dermatitis (eczema). He has held leadership positions at NeurogesX, Inc., Cerus Corporation, and PPD-Development. Dr. Chanda has over thirty publications in various peer-reviewed journals. He received his Ph.D. in Pharmacology/Toxicology at Northeast Louisiana University and completed postdoctoral fellowships at the University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, North Carolina.
Lucy O. Day
Chief Financial Officer
Ms. Day is AN2’s Chief Financial Officer, Secretary and Treasurer, responsible for finance, human capital, and administrative functions. Previously, Ms. Day led a number of finance and administrative functions at Anacor Pharmaceuticals over a 14-year period, initially as CFO, then focusing on legal matters and human resources. While at Anacor, Ms. Day built and led the Finance and Accounting functions, and was instrumental in preparing for and completing private and public financings, drug product launches, and numerous research and development collaborations. In the earlier years, Ms. Day reviewed and oversaw legal matters of the Company, and subsequently led the HR function during commercialization of Eucrisa®, acquisition by Pfizer, and subsequent transition into Pfizer’s culture. Prior to Anacor, Ms. Day served in a similar capacity as CFO at Centaur Pharmaceuticals, where she helped grow the startup from early research to late-stage clinical development. Ms. Day started her career at Ernst & Young and has previous financial experience at Sohio Petroleum and as a VP at Bank of America. She is a University of California, Berkeley graduate and is a CPA (non-active) in California.
Paul Eckburg, M.D.
Chief Medical Officer
Paul Eckburg, M.D., an infectious diseases physician and Chief Medical Officer of AN2, has worked in clinical research and anti-infective drug development for over 20 years. Dr. Eckburg has served as acting CMO for Zavante Therapeutics, Geom Therapeutics, Utility Therapeutics, and Bugworks Research, among others. He has been involved in the development of multiple approved anti-infective products, including ceftaroline fosamil (Teflaro®), inhaled levofloxacin (Quinsair™), ceftazidime-avibactam (Avycaz®), and omadacycline (Nuzyra®). Dr. Eckburg received his Bachelor of Science in Cell and Structural Biology from the University of Illinois at Urbana-Champaign and his M.D. from Rush University. He completed both Internal Medicine residency and Infectious Diseases fellowship at Stanford University School of Medicine, where he continues to teach as an Adjunct Clinical Assistant Professor.
Josh Eizen
Chief Legal Officer and Secretary
Mr. Eizen is AN2’s Chief Legal Officer and Secretary, responsible for managing the company’s legal affairs and compliance functions. He has been practicing law for over 20 years, with roles spanning industry, government, and private practice. Before joining AN2, Mr. Eizen held senior legal and compliance positions at Jazz Pharmaceuticals, GW Pharmaceuticals, Jansen Pharmaceuticals, and Actelion Pharmaceuticals. As the U.S. General Counsel at GW, he guided the company on corporate, commercialization, regulatory, government affairs, and employment matters. He supported the launch and commercialization of Epidiolex, GW’s $7.2b sale to Jazz Pharmaceuticals, its $350m follow-on offering (2018), and various pre-commercial and regulatory strategies for GW’s neuroscience and orphan-disease pipeline. Earlier in his career, Mr. Eizen was Associate Chief Counsel for Enforcement at the Food and Drug Administration. As a government attorney for FDA, he handled investigations and prosecutions involving off-label promotion, manufacturing violations, product integrity, and public health outbreaks. Mr. Eizen began his legal career in private practice at a corporate tax and litigation firm.
Kevin Krause, BS, MBA
Chief Strategy Officer
Mr. Krause has more than 20 years of experience in the biopharmaceutical industry, spanning R&D, Corporate Business Development, Commercial Strategy, and Operations within Infectious Diseases and Respiratory Medicine. He has been a key contributor and team-leader for three US INDs, five New Drug Applications (NDAs), five Marketing Authorization Applications (MAAs), four US FDA Anti-infective Drug Advisory Committee meetings, and numerous product launches in both the US and Europe. Prior to joining AN2 Therapeutics, Mr. Krause was the Sr. Director and Head of Microbiology and later the Sr. Director of Corporate Development at Achaogen. Previously, Mr. Krause was a member of the Clinical Microbiology team at Cerexa, Inc. (A subsidiary of Forest Laboratories/Actavis/Allergan now Abbvie) and played a key role on the Scientific Assessment teams for all antibacterial and antiviral in-licensing opportunities. Previously he served in various Research and Clinical Microbiology roles at Theravance. Mr. Krause has been instrumental in the clinical development and approval of ZEMDRI® (plazomicin), AVYCAZ® (ceftazidime-avibactam) and VIBATIV® (telavancin), contributed to the approval and launch of Teflaro® (ceftaroline fosamil) and represented the Microbiology function on the global product teams for Colobreathe® (inhaled colistin) and Quinsair® (inhaled levofloxacin). He is an author of >50 peer-reviewed publications and more than 150 meeting abstracts. He has been an invited speaker at a number of industry related forums and conferences and FDA and EMA guidance document development workshops. Mr. Krause earned an MBA from the University of California, Berkeley Haas School of Business, and a BS in Cell and Molecular Biology from San Francisco State University.
Jennifer Huber
SVP, Regulatory Affairs and Quality
Ms. Huber has more than 20 years of regulatory and quality assurance experience in the biopharmaceutical industry spanning multiple therapeutic areas with a special emphasis on rare and infectious bacterial and viral diseases. She has led the global, U.S., and regional regulatory process for numerous investigational and marketed small molecule, mAb, and cell & gene therapy products, including New Drug Applications in both the U.S. and Japan, as well as Biologics License Applications, and Marketing Authorization Applications. Prior to joining AN2 Therapeutics, Ms. Huber served as an independent regulatory consultant in the biopharmaceutical industry and held senior in-house roles at Prothena, Iovance and Sangamo leading regulatory strategy. She has also held leadership roles at Gilead and Exelixis in Regulatory Affairs, Regulatory Operations, and Medical Writing. Ms. Huber earned an MS in Biology from Penn State University and a BS in Biology and Spanish from Vanderbilt University.
Board of Directors
Co-Founder
Chair Of The Board Of Directors
Co-Founder, President & CEO
Director
Adjuvant Capital, Principal
Director
Mountain Group Partners, Managing Director
Director
PRESIDENTIAL ADVISORY COUNCIL FOR COMBATING ANTIBIOTIC-RESISTANT BACTERIA; FORMER WW HEAD OF INFECTIOUS DISEASE R&D AT GSK DIRECTOR
Calithera Biosciences, Chief Financial Officer
Director
Biocrossroads, President & CEO
Director
Global Alliance for TB Drug Development, President & CEO
DIRECTOR
Fitzpatrick & Co, Founder and Chief Executive Officer
Director
Joseph S. Zakrzewski
Co-Founder
Chair Of The Board Of Directors
Mr. Zakrzewski has over 25 years of experience as an executive in the biotechnology and pharmaceutical industry. He currently serves on the Board of Directors of publicly held companies Acceleron Pharmaceuticals, Amarin Pharmaceuticals, and Sangamo Therapeutics. Mr. Zakrzewski also serves on the board of a number of privately held companies, is the founder of a number of biotechnology companies, and is involved in a number of philanthropic activities. He was Chairman and CEO of Amarin Pharmaceuticals, a publicly traded company focused on the development and commercialization of cardiovascular drugs based on Omega 3‘s from 2010 to 2013, successfully developing and launching Vascepa®. Mr. Zakrzewski served as a Venture Partner with Orbimed, in 2010 and 2011. Prior to this, he was Chairman, President & Chief Executive Officer of Xcellerex, a privately held company focusing on commercializing its proprietary next generation manufacturing technology for biotherapeutics and vaccines from 2007 to 2010. Mr. Zakrzewski also served as the Chief Operating Officer of Reliant Pharmaceuticals, a specialty pharmaceutical company focused on cardiovascular drugs from 2005 to 2007. Mr. Zakrzewski had responsibility for the company’s pharmaceutical operations including, R&D, business development, supply chain/manufacturing, quality, IT, and compliance. Prior to this, Mr. Zakrzewski served in a variety of executive level capacities at Eli Lilly & Company for 17 years including R&D, manufacturing, finance and business development. His most recent position, Senior Vice President, had global responsibility for all business and corporate development. Mr. Zakrzewski is an inventor on multiple US patents and has been involved in or led financings amounting to several billion dollars for both private and public companies. Over his career, he has served as a member of the board of directors of over 25 companies. He received a BS in Chemical Engineering from Drexel University in 1986, an MS in Biochemical Engineering from Drexel University in 1988, and an MBA in Finance in 1992 from Indiana University.
Eric Easom
Co-Founder, President & CEO
Director
Mr. Easom has over 29 years of leadership experience in the biotechnology and pharmaceutical industry and has spent the last 15 years focused on bringing innovation to address significant unmet needs in infectious diseases, focused on the developing world. In addition to being the Founder, President and CEO of AN2 Therapeutics, Mr. Easom also serves on the Board of Directors of AN2 Therapeutics. Mr. Easom serves on the Board of Directors for the Chagas Disease Foundation, Resilient Biotics, and is an advisor for the California Life Sciences Institute. Previously, Mr. Easom spent 9 years at Anacor Pharmaceuticals, which was acquired by Pfizer. During his tenure, he led Anacor’s R&D on neglected disease programs that achieved global prominence, working in close partnership with the Bill and Melinda Gates Foundation, the Wellcome Trust, The University of Georgia (Tarleton Lab), Medicines for Malaria Venture, Global Alliance for Veterinary Medicine, Drugs for Neglected Disease initiative (DNDi), GlaxoSmithKline (GSK), Eli Lilly & Company, the University of California, San Francisco, Colorado State, DTRA, Walter Reed, the London School of Hygiene and Tropical Medicine, TB Alliance, the global Anti-Wolbachia Consortium, and numerous other partners. The Anacor Neglected Diseases team raised over $80M in funding and discovered over a dozen potentially transformational medicines for diseases such as malaria, tuberculosis, river blindness, cryptosporidiosis and trypanosome diseases including Chagas disease, African sleeping sickness, and leishmaniasis. Mr. Easom also served on the Board of Directors for the Infectious Disease Research Institute, from 2007-2014, serving as Chairman from 2009-2013. The majority of his early career was at Eli Lilly and Company, followed by McKesson and other biotechnology companies such as MedImmune and InteKrin Therapeutics. Mr. Easom earned an MBA from Indiana University, Kelley School of Business and a BS and Masters in Electrical Engineering from the University of Louisville.
Kabeer Aziz
Adjuvant Capital, Principal
Director
Mr. Aziz is a cofounder of Adjuvant Capital, following three years with the Global Health Investment Fund (GHIF), where he was responsible for sourcing and analyzing new opportunities, including co-leading the fund’s investments in Univercells, Themis, Access Bio, and Atomo Diagnostics. He has supported projects across the entire GHIF portfolio and continues to be involved as a board observer to several active partnerships.
Prior to GHIF, Kabeer was an investment professional at Metalmark Capital, a private equity fund in New York, where he focused primarily on medical device investments. Kabeer also spent time at Greenhill & Co., a boutique investment bank, where he advised on M&A transactions in the biopharmaceutical and medical technology sectors. He graduated with honors from the Stern School of Business at New York University with a BS in Finance & Economics.
Rob Readnour, Ph.D.
Mountain Group Partners, Managing Director
Director
Dr. Readnour currently serves on or has visitation rights to the following companies: AgTech Accelerator, a unique startup accelerator focused on discovering and developing emerging agricultural technology companies; Skyline Vet Pharma, a company that is developing veterinary pharmaceuticals using proven delivery technologies to reformulate drugs with established animal health markets; Boragen, a company that is developing small molecule approaches focused on leveraging the unique chemical properties of boron chemistry, both in crop protection and animal health; Applied LifeSciences & Systems Poultry, a poultry vaccine delivery device company developing a high-throughput vaccine delivery system to individually vaccinate post-hatch chicks; and Convetra, a company developing a radiosynoviorthesis product to treat chronic osteoarthritis in dogs.
Prior to joining MGP, Dr. Readnour worked at Elanco Animal Health for 27 years, where he held several senior management positions in which he was responsible for developing and executing Elanco’s Research and Development strategies for entering several new business areas (companion animal pharmaceuticals, vaccines and enzymes). Dr. Readnour played an important role in Elanco’s acquisition and integration of Novartis Animal Health, Lohmann Animal Health, ChemGen and Janssen Animal Health, and he developed and led Elanco’s new technology scouting, acquisition and due diligence efforts. Dr. Readnour served as a member of the Food and Agriculture Section of Bio International Board and as an External Advisory Board member for University of Illinois Animal Science Department.
Prior to Elanco, Dr. Readnour was an internationally recognized expert on animal health product development, analytical chemistry, human food safety and drug residues with 11 publications and 14 external presentations. Throughout his career, Dr. Readnour was responsible for the development and commercialization of 10 animal health products. Dr. Readnour received his PhD in Analytical Chemistry from University of Illinois in 1990.
Lynn Marks, M.D.
PRESIDENTIAL ADVISORY COUNCIL FOR COMBATING ANTIBIOTIC-RESISTANT BACTERIA; FORMER WW HEAD OF INFECTIOUS DISEASE R&D AT GSK DIRECTOR
Dr. Marks has over 30 years of experience in the field of infectious diseases and as a senior executive in the pharmaceutical industry. He led the infectious disease therapy area for GlaxoSmithKline for a decade and later retired as a Senior Vice President in R&D, with accountability as Chief Research Practices Officer across the Pharmaceutical, Vaccines, and Consumer Healthcare R&D organizations, as well as being Senior Clinical Advisor for Infectious Diseases. His extensive experience ranges across antibacterials, antivirals, including HIV/AIDS, and neglected tropical diseases. For over 10 years, he has also served on the Scientific Advisory Board for the TB Alliance, a not-for-profit organization, including as Chair. He also served as Vice President at Tunnell Government Services and, as a contractor, supported the Office of the Director for the Biomedical Advanced Research and Development Authority (BARDA) focusing on emerging infectious disease threats, antimicrobial resistance, and the clinical development of medical countermeasures. In addition, Dr. Marks was a member of the Advisory Committee for the National Center for Advancing Translational Sciences at NIH and Chairs the Cures Acceleration Network Review Board for the National Center for Advancing Translational Sciences (NCATS). Most recently, he joined the Scientific Review Board for the Medicines for Malaria Venture (MMV), the leading not-for- profit product development partnership in the field of antimalarial drug research and development. Dr. Marks’ career began with a faculty position at the University of South Alabama College of Medicine in the Infectious Diseases group where he held teaching and patient care responsibilities, as well as a NIH-funded Physician Scientist Award investigating molecular mechanisms of bacterial pathogenicity. He is Board Certified in Internal Medicine and Infectious Diseases.
Stephanie Wong
Calithera Biosciences, Chief Financial Officer
Director
Ms. Wong has over 20 years of finance and accounting experience in public and private companies within the biotechnology industry. Currently, Ms. Wong serves as Chief Financial Officer and Secretary of Calithera Biosciences (NASDAQ: CALA). Prior to joining Calithera, Ms. Wong served as Vice President, Finance and Controller at SciClone Pharmaceuticals and in senior finance roles at AcelRx Pharmaceuticals and Kosan Biosciences. Ms. Wong received a B.S. in Business Administration from the University of California, Berkeley and is a Certified Public Accountant (inactive) in the State of California.
Patricia Martin
Biocrossroads, President & CEO
Director
Ms. Martin has over 25 years of biopharmaceutical leadership experience across multiple therapeutic areas and disciplines. A former Eli Lilly and Company executive, Ms. Martin was the Chief Operating Officer of Lilly Diabetes as well as Lilly’s corporate Chief Diversity Officer and Chief Alliance Officer. During her career at Lilly, she also held leadership roles in strategy, finance, clinical product development, human resources, and investor relations. Since 2019, Ms. Martin has served as the President and CEO of BioCrossroads, where she is focused on growing Indiana’s life sciences sector, through research and education, seed funds, and economic development. Ms. Martin received a B.S. in Accounting from Indiana University, an M.B.A. from Harvard Business School, and is a Certified Public Accountant (inactive) in the State of Arizona.
Melvin Spigelman, M.D.
Global Alliance for TB Drug Development, President & CEO
Director
Dr. Melvin Spigelman is President and CEO of the Global Alliance for TB Drug Development (TB Alliance) and serves as Co-Chair of the Working Group on New TB Drugs of the Stop TB Partnership. Prior to joining the TB Alliance, he served in leading research and development positions at Knoll Pharmaceuticals, a pharmaceutical unit of BASF Corporation, including as Vice President, Global Clinical Centers. In addition, Dr. Spigelman has served as a board member of multiple publicly listed biotechnology companies, including The Medicines Company (acquired by Novartis). He holds a Doctor of Medicine degree from the Mount Sinai School of Medicine, where he also worked as an Associate Professor.
Maggie FitzPatrick
Fitzpatrick & Co, Founder and Chief Executive Officer
Director
Ms. FitzPatrick is a recognized leader in the area of corporate affairs, marketing and business operations. She has served in leadership positions in the public, private and non-profit sectors and brings a breadth of experience in healthcare, climate change and global health. Before starting her own consultancy, she led corporate affairs, marketing and philanthropy for Exelon, a Fortune 200 clean energy provider. Prior to Exelon, she led global communications and public affairs at Johnson & Johnson. Before Johnson & Johnson, she served as Chief Communications Officer and president of the Foundation at Cigna, a multinational health services and insurance corporation.
Ms. FitzPatrick is a member of the board of directors at VistaGen Therapeutics, a NASDAQ listed, late-stage central nervous system-focused biopharmaceutical company. She was named one of the most influential global communications professionals in multiple years by PR Week Magazine and recognized as a top c-suite executive by Washington Business Journal in 2019. Ms. FitzPatrick holds a Bachelor of Arts in English and Public Policy from Syracuse University and a Master of Arts in Public Policy from The George Washington University. She completed the board directorship program at the Harvard Business School and is certified as a corporate director by the National Association of Corporate Directors. Appointed in 2020 by Mayor Muriel Bowser and approved by the Council of the District of Columbia, Ms. FitzPatrick serves as Commissioner and Vice Chairperson of the DC Commission on the Arts and Humanities.
Founders
AN2’s founders are an accomplished group of scientific and business leaders in the field of infectious diseases. Their vast knowledge and understanding of boron chemistry and infectious diseases will help guide our plans for the rapid development of treatments for multiple infectious diseases.
Our founders include Eric Easom, President and CEO of AN2 Therapeutics, and a leading infectious diseases expert who recognized the potential of epetraborole and exclusively licensed this asset. Our team also includes George Talbot, MD, Senior Clinical Advisor, Joseph Zakrzewski, Co-Founder and Chair of the Board of Directors, and Dickon Alley, Ph.D., Head of Biology.
Co-Founder, President & CEO
Director
Co-Founder
Chair of The Board of Directors
George H. Talbot, M.D., FACP, FIDSA
Co-Founder & Senior Clinical Advisor
Michael R.K. (Dickon) Alley, Ph.D.
Co-Founder & Head of Biology
Eric Easom
Co-Founder, President & CEO
Director
Mr. Easom has over 29 years of leadership experience in the biotechnology and pharmaceutical industry and has spent the last 15 years focused on bringing innovation to address significant unmet needs in infectious diseases, focused on the developing world. In addition to being the Founder, President and CEO of AN2 Therapeutics, Mr. Easom also serves on the Board of Directors of AN2 Therapeutics. Mr. Easom serves on the Board of Directors for the Chagas Disease Foundation, Resilient Biotics, and is an advisor for the California Life Sciences Institute. Previously, Mr. Easom spent 9 years at Anacor Pharmaceuticals, which was acquired by Pfizer. During his tenure, he led Anacor’s R&D on neglected disease programs that achieved global prominence, working in close partnership with the Bill and Melinda Gates Foundation, the Wellcome Trust, The University of Georgia (Tarleton Lab), Medicines for Malaria Venture, Global Alliance for Veterinary Medicine, Drugs for Neglected Disease initiative (DNDi), GlaxoSmithKline (GSK), Eli Lilly & Company, the University of California, San Francisco, Colorado State, DTRA, Walter Reed, the London School of Hygiene and Tropical Medicine, TB Alliance, the global Anti-Wolbachia Consortium, and numerous other partners. The Anacor Neglected Diseases team raised over $80M in funding and discovered over a dozen potentially transformational medicines for diseases such as malaria, tuberculosis, river blindness, cryptosporidiosis and trypanosome diseases including Chagas disease, African sleeping sickness, and leishmaniasis. Mr. Easom also served on the Board of Directors for the Infectious Disease Research Institute, from 2007-2014, serving as Chairman from 2009-2013. The majority of his early career was at Eli Lilly and Company, followed by McKesson and other biotechnology companies such as MedImmune and InteKrin Therapeutics. Mr. Easom earned an MBA from Indiana University, Kelley School of Business and a BS and Masters in Electrical Engineering from the University of Louisville.
Joseph S. Zakrzewski
Co-Founder
Chair of The Board of Directors
Mr. Zakrzewski has over 25 years of experience as an executive in the biotechnology and pharmaceutical industry. He currently serves on the Board of Directors of publicly held companies Acceleron Pharmaceuticals, Amarin Pharmaceuticals, and Sangamo Therapeutics. Mr. Zakrzewski also serves on the board of a number of privately held companies, is the founder of a number of biotechnology companies, and is involved in a number of philanthropic activities. He was Chairman and CEO of Amarin Pharmaceuticals, a publicly traded company focused on the development and commercialization of cardiovascular drugs based on Omega 3‘s from 2010 to 2013, successfully developing and launching Vascepa®. Mr. Zakrzewski served as a Venture Partner with Orbimed, in 2010 and 2011. Prior to this, he was Chairman, President & Chief Executive Officer of Xcellerex, a privately held company focusing on commercializing its proprietary next generation manufacturing technology for biotherapeutics and vaccines from 2007 to 2010. Mr. Zakrzewski also served as the Chief Operating Officer of Reliant Pharmaceuticals, a specialty pharmaceutical company focused on cardiovascular drugs from 2005 to 2007. Mr. Zakrzewski had responsibility for the company’s pharmaceutical operations including, R&D, business development, supply chain/manufacturing, quality, IT, and compliance. Prior to this, Mr. Zakrzewski served in a variety of executive level capacities at Eli Lilly & Company for 17 years including R&D, manufacturing, finance and business development. His most recent position, Senior Vice President, had global responsibility for all business and corporate development. Mr. Zakrzewski is an inventor on multiple US patents and has been involved in or led financings amounting to several billion dollars for both private and public companies. Over his career, he has served as a member of the board of directors of over 25 companies. He received a BS in Chemical Engineering from Drexel University in 1986, an MS in Biochemical Engineering from Drexel University in 1988, and an MBA in Finance in 1992 from Indiana University.
George H. Talbot, M.D., FACP, FIDSA
Co-Founder & Senior Clinical Advisor
Dr. Talbot, an infectious diseases physician trained at the University of Pennsylvania Medical Center, began his pharmaceutical career in anti-infective drug development at Rhone-Poulenc Rorer, subsequently Aventis. He founded his consultancy firm, Talbot Advisors LLC, in 2000. Dr. Talbot later served as Executive Vice President/Chief Medical Officer of Cerexa Inc. (purchased by Forest Laboratories) and worked closely with the development teams at Calixa Therapeutics (acquired by Cubist Pharmaceuticals) and Durata Therapeutics (purchased by Actavis Plc). He was a founding member of IDSA's Antimicrobial Availability Task Force ("Bad Bugs, No Drugs"), recently sat on IDSA’s Antimicrobial Resistance Committee, was a committee member of the CLSI (previously NCCLS), and is past co-chair of the ABSSSI/CABP and HABP/VABP Clinical Trial Endpoint Development Project Teams at the Biomarkers Consortium of the Foundation of the National Institutes of Health. He has co-authored more than 100 publications in peer-reviewed scientific journals.
Michael R.K. (Dickon) Alley, Ph.D.
Co-Founder & Head of Biology
Dr. M.R.K. (Dickon) Alley has over 30 years of experience in microbiology from academia and industry. Dr. Alley led Discovery Biology at Anacor Pharmaceuticals for 15 years, starting from the company’s inception. At Anacor, he and his team elucidated the novel OBORT Leucyl-tRNA synthetase mechanism of action for Kerydin®, an FDA-approved treatment for onychomycosis. This led to the discovery of two novel phase 2 antibacterials currently in development. He also led several early phase antibacterial drug discovery programs funded by the Bill & Melinda Gates Foundation and Defense Threat Reduction Agency. Dr. Alley has co-authored over 30 publications in peer-reviewed journals, including seminal publications in the journal Science. He earned his PhD in Biological Sciences from the University of Warwick after completing his BSc ARCS in Biochemistry from Imperial College London. He then completed Post-doctoral Fellowships at Columbia University and Stanford University in the lab of Dr. Lucy Shapiro before he was awarded a Royal Society University Research Fellowship.
Partners
AN2 Therapeutics has a strategic partnership with Brii Biosciences, a clinical-stage company committed to serving patients’ needs and improving public health in China and around the world. The company has licensed rights to Brii Biosciences to develop, manufacture, and commercialize certain compounds, including epetraborole, in China, Hong Kong, Taiwan, and Macau.
